Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1424&sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1425&sort=awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1423&sort=awardee_organization" }, "data": [ { "type": "Grant", "id": "15893", "attributes": { "award_id": "1U18FD008634-01", "title": "Increased Extraction Capacity for Molecular Section", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 44330, "first_name": "MEGAN", "last_name": "MILLER", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-20", "end_date": "2026-08-31", "award_amount": 31722, "principal_investigator": { "id": 44331, "first_name": "YAN", "last_name": "ZHANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3378, "ror": "", "name": "UNIVERSITY OF ARIZONA", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "Vet-LIRN Network Capacity-Building Project and Equipment Grants (U18) PAR-23-202 Increased Extraction Capacity for Arizona Veterinary Diagnostic Laboratory Molecular Section Project Summary/Abstract- The Arizona Veterinary Diagnostic Laboratory (AZVDL) is seeking funding to purchase an Indical IndiMag2 to enhance its nucleic acid extraction capability and capacity, thereby strengthening its emergency surge testing for significant animal food/feed emergency events. Veterinary diagnostic laboratories play a critical role in protecting both animal and public health, especially during large-scale foodborne disease outbreaks or contamination incidents. Funding through the Vet-LIRN Network Capacity-Building Project and Equipment Grants (U18) is essential to expand AZVDL’s ability to respond effectively to such emergencies. This support will enable AZVDL to improve its diagnostic capabilities by acquiring advanced equipment. The COVID-19 pandemic has demonstrated that veterinary laboratories are uniquely positioned to provide high-throughput testing during public health crises, as they routinely handle large- scale diagnostic procedures for zoonotic and animal diseases. By enhancing its capacity, AZVDL will be better equipped to provide real-time detection of pathogens or contaminants in animal food and feed, helping to prevent outbreaks that threaten food safety, public health, and economic stability. This funding initiative also aligns with the goals of the Food Safety Modernization Act (FSMA), which emphasizes proactive measures to detect and prevent foodborne illnesses. Upgrading AZVDL’s infrastructure will not only improve its response to emerging threats but also contribute to the broader national network of veterinary laboratories dedicated to safeguarding both animal and human populations.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "16127", "attributes": { "award_id": "1R25AI189409-01", "title": "The National Summer Undergraduate Research Project: Virtual Programming and Mentoring in Biomedical Microbiology and Immunology", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44608, "first_name": "CARMEN", "last_name": "MOTEN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-05-13", "end_date": "2031-04-30", "award_amount": 368681, "principal_investigator": { "id": 44609, "first_name": "Michael David Leslie", "last_name": "Johnson", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3378, "ror": "", "name": "UNIVERSITY OF ARIZONA", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Summer Undergraduate Research Project (NSURP) was created as an eight-week virtual summer research program in the microbial sciences that matches underrepresented minorities in STEM undergraduate students nationwide with faculty mentors worldwide to address the barriers presented by COVID-19 cancelations. NSURP mentees conduct research from any location with an internet connection, allowing students to learn how to conduct impactful research by forming and testing hypotheses. As individuals returned to in-person programs, NSURP found a population unable to travel, independent of COVID-19, due to financial, familial, geography, and health constraints. As we see an increased demand from these individuals, post-pandemic, who can’t travel to in-person opportunities, we seek to expand our ability to serve these undergraduates with research opportunities in our program and provide them with year-long mentoring and professional development. NSURP seeks to apply its virtual research model to human health-related topics, such as the basic and applied disease research conducted within the purview of the NIAID, both in microbiology and immunology. Implementing NSURP within the NIAID infrastructure will create more opportunities for URM scientists and ultimately aid in developing a diverse biomedical research workforce. The central premise of NSURP is to meet undergraduates where they are, facilitate exposure and pursuit of a scientific opportunity, and give them the tools and confidence to continue in their scientific careers. To maximize the contribution of NSURP within the NIAID mission, we will 1) provide virtual biomedical-specific summer research opportunities within the NIAID mission for minoritized undergraduates, 2) facilitate synergistic virtual scientific and career multi-level mentoring relationships, and 3) assess program impact by evaluating educational outcomes of NSURP participants and conducting longitudinal studies on the effects of culturally-responsive virtual mentorship training.", "keywords": [ "Address", "American", "Arizona", "Basic Science", "Biological Sciences", "Biomedical Research", "Black race", "COVID-19", "Caliber", "Collaborations", "Development", "Discipline", "Disease", "Education", "Education Projects", "Enrollment", "Faculty", "Family", "First Generation College Students", "Foundations", "Funding", "Geography", "Health", "Health Professional", "Human", "Immunology", "Indigenous", "Individual", "Infrastructure", "Internet", "Interview", "Latina", "Latino", "Latinx", "Learning", "Location", "Longitudinal Studies", "Low income", "Mentors", "Mentorship", "Microbiology", "Minority Groups", "Mission", "Modeling", "National Institute of Allergy and Infectious Disease", "Outcome", "Participant", "Persons", "Population", "Positioning Attribute", "Productivity", "Readiness", "Research", "Research Project Grants", "Research Training", "Resources", "STEM career", "STEM field", "Scholars Program", "Science", "Science Technology Engineering and Mathematics", "Societies", "Students", "Surveys", "Testing", "Training", "Training Activity", "Trajectory", "Travel", "Underrepresented Minority", "Underrepresented Populations", "United States", "Universities", "career", "design", "experience", "faculty mentor", "improved", "interest", "meetings", "microbial", "minority scientist", "minority undergraduate", "peer", "peer coaching", "post-pandemic", "programs", "skill acquisition", "summer research", "tool", "training opportunity", "undergraduate student", "undergraduate summer research", "underrepresented minority student", "virtual" ], "approved": true } }, { "type": "Grant", "id": "15852", "attributes": { "award_id": "4R00AA031315-02", "title": "Characterization of acetaldehyde-protein adducts in alcohol-associated liver disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 44271, "first_name": "LI", "last_name": "LIN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-23", "end_date": "2028-08-31", "award_amount": 249000, "principal_investigator": { "id": 44272, "first_name": "Bryan R.", "last_name": "Mackowiak", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3379, "ror": "", "name": "EAST TENNESSEE STATE UNIVERSITY", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "Ethanol consumption has been on the rise throughout the COVID-19 pandemic and one of the major consequences has been a surge in alcohol-associated liver disease (ALD), especially severe alcoholic hepatitis (sAH). sAH is a life-threatening condition with 30-day patient mortality greater than 30%, limited treatment options, and often requires a liver transplant. There is an urgent need to identify novel mechanisms of ALD progression that are potential targets for treatment. The ethanol metabolite acetaldehyde (AcH) is known to form adducts on lysine residues within proteins, which affect protein function. Many proteins are known to bind to AcH, but no one has characterized the overall composition or downstream effects of these protein modifications on the pathogenesis of ALD. Albumin is one of the major proteins known to bind to AcH, and these AcH adducts mostly occur on the many exposed lysine residues throughout the albumin molecule. The fact that a single albumin can bind many AcH molecules combined with albumin being the most abundant protein in the liver and circulation means that albumin may act as a “sponge” for excess AcH. Therefore, any decrease in albumin levels may lead to increased modification of other proteins, having deleterious effects on ethanol-induced organ injury. My preliminary data shows that plasma albumin levels are decreased in heavy drinkers compared to control subjects in the absence of liver dysfunction. In albumin-deficient mice, ethanol feeding leads to decreased lymphocyte accumulation in the liver, but the mechanism is unknown. This project is designed to test the overarching hypothesis that albumin alters the distribution of AcH-protein adducts after ethanol consumption, modulating lymphocyte function in ALD. In Aim 1 (K99 phase) I will receive training from my mentor, Dr. Bin Gao, to determine how AcH and albumin regulate lymphocyte function. In Aim 2 (K99 phase), I will receive training in proteomic methods and analysis from my committee member Dr. Fritz to characterize the AcH-protein adductome in immune cells and albumin-deficient mice. In Aim 3 (R00 phase), I will use the training from the K99 phase to analyze public proteomic datasets and identify specific AcH-protein adducts that are present in patients with ALD. I will utilize cellular models to determine how these modifications impact immune cell and hepatocyte functions in the context of ALD. This project will provide a framework for how AcH-protein adducts modulate ALD using albumin as a model protein. The training provided by this grant will provide the PI with a strong foundation to achieve his long-term goal of identifying systemic mediators of ethanol-induced liver injury to develop therapeutics that protect against alcohol-induced injury in multiple ways. The NIAAA will provide an ideal environment for cross-disciplinary training and the necessary resources to transition to independence.", "keywords": [ "Acetaldehyde", "Address", "Affect", "Albumins", "Alcohol consumption", "Alcohol-Induced Disorders", "Alcoholic Hepatitis", "Alcoholic Liver Diseases", "Alcoholic beverage heavy drinker", "Amino Acids", "Binding", "CD3 Antigens", "COVID-19 pandemic", "Cell Physiology", "Cell model", "Cells", "Chronic", "Circulation", "Coculture Techniques", "Committee Members", "Cytoskeleton", "Data", "Data Analyses", "Data Set", "Defect", "Development", "Disease Progression", "Environment", "Ethanol", "Ethanol Metabolism", "Event", "Exhibits", "Foundations", "Goals", "Grant", "Hepatocyte", "Human", "Immune", "Impairment", "Infiltration", "Inflammation", "Life", "Liver", "Liver Dysfunction", "Liver diseases", "Lymphocyte", "Lymphocyte Count", "Lymphocyte Function", "Lysine", "Mediating", "Mediator", "Mentors", "Methods", "Modeling", "Modification", "Mus", "National Institute on Alcohol Abuse and Alcoholism", "Pathogenesis", "Patients", "Persons", "Phase", "Plasma", "Plasma Albumin", "Play", "Population", "Porifera", "Post-Translational Protein Processing", "Pre-Clinical Model", "Proliferating", "Proteins", "Proteomics", "Resources", "Role", "Sampling", "Splenocyte", "T-Lymphocyte", "Testing", "Therapeutic", "Training", "Work", "adduct", "alcohol use disorder", "comparison control", "design", "feeding", "immunoregulation", "liver injury", "liver metabolism", "liver transplantation", "mortality", "mouse model", "novel", "organ injury", "protein function" ], "approved": true } }, { "type": "Grant", "id": "15853", "attributes": { "award_id": "1F31NS143332-01", "title": "Early life influenza infection and glial dysregulation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 44273, "first_name": "JENNY LILY", "last_name": "KIM", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-01", "end_date": "2028-08-31", "award_amount": 49538, "principal_investigator": { "id": 44274, "first_name": "Karen Elizabeth", "last_name": "Malacon", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3380, "ror": "", "name": "STANFORD UNIVERSITY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Millions of children in the United States contract respiratory infections such as influenza, RSV, and COVID-19 every year, with those under the age of five affected the most severely1,2. Respiratory infections can have long- term effects on the central nervous system in both adults and children3–11. In fact, currently, 6 million children are suffering from long COVID, and up to 44% of these children experience cognitive impairment3. Childhood is a critical period for synaptic formation and myelination, making the brain particularly vulnerable to insults that can lead to permanent and long-lasting neurocognitive changes12. In rodents, postnatal day (P)14 is a crucial period of peak synaptogenesis and myelination12–14. As a result, during this time, a respiratory immune challenge such as influenza can result in persistent neurodevelopmental dysfunction. While many studies have investigated the neurological effects of systemic immune challenges during the prenatal and adult periods15–18, the impact of influenza infection during early postnatal life remains understudied. The proposed study aims to investigate the effect of influenza infection at P14 on glial dysregulation in mice. The overarching hypothesis is that influenza infection results in multicellular dysfunction driven by aberrant microglia. My preliminary data show that influenza infection at P14 leads to an increase in reactive microglia one-week post-infection in the cingulum and dentate gyrus, along with elevated expression of inflammatory genes in microglia as revealed by single-nuclei RNA sequencing. I will employ advanced transcriptomic analysis to examine changes in glial sub-states, and to identify alterations in synapse/pruning-associated genes (Aim 1A). Additionally, changes in microglia-mediated synaptic pruning will be assessed using Imaris 3D reconstructions to quantify microglial engulfment of synapses following infection. My preliminary findings indicate that influenza infection results in a decrease in OPCs and oligodendrocytes in the cingulum and dentate gyrus one-week post-infection. I will use an established optogenetics paradigm19,20 to stimulate excitatory dentate gyrus neurons and test for changes in activity- dependent myelination following infection (Aim 2). Finally, based on the hypothesis that reactive microglia dysregulate oligodendroglial dynamics, microglia will be depleted between P7-P21 to determine if this rescues the observed loss of oligodendroglial cells (Aim 3). Given my experiences investigating the impact of prenatal environmental immune challenges on microglia and behavior, I am well-prepared to execute these experiments. This work will be conducted under the sponsorship of Michelle Monje, MD/PhD, a leading expert in glial-neuron interactions and myelin plasticity. The co-sponsorship of Catherine Blish, MD/PhD, will ensure comprehensive guidance on virologic aspects, and collaborations with Karl Deisseroth, MD/PhD, Akiko Iwasaki, PhD, and Beth Stevens, PhD, will provide the necessary support to successfully achieve the aims of this project. Stanford's rigorous training environment and the collective support from these experts will ensure the project's success and my growth into an innovative physician-scientist capable of developing therapies for neuroimmune diseases.", "keywords": [ "3-Dimensional", "Adult", "Affect", "Age", "Axon", "Behavior", "Brain", "COVID-19", "COVID-19 pandemic", "CSF1R gene", "Cd68", "Cell Lineage", "Cells", "Central Nervous System", "Child", "Childhood", "Cognitive", "Collaborations", "Contracts", "Data", "Data Set", "Development", "Doctor of Philosophy", "Ensure", "Environment", "Functional disorder", "Future", "Genes", "Goals", "Growth", "Homeostasis", "Hospitalization", "Immune", "Immunohistochemistry", "Impaired cognition", "Infection", "Inflammatory", "Influenza", "Institution", "Intraperitoneal Injections", "Life", "Light", "Long COVID", "Long-Term Effects", "MHC Class I Genes", "Mediating", "Microglia", "Mus", "Myelin", "Neurobiology", "Neurocognitive", "Neuroimmune", "Neurologic Effect", "Neurons", "Oligodendroglia", "Parahippocampal Gyrus", "Physicians", "Physiologic pulse", "Play", "Process", "Proliferating", "Research", "Respiratory System", "Respiratory Tract Infections", "Rodent", "Role", "Scientist", "Synapses", "Testing", "Time", "Training", "Transmission Electron Microscopy", "United States", "Virus", "Work", "age group", "chemokine", "confocal imaging", "critical period", "cytokine", "density", "dentate gyrus", "experience", "experimental study", "influenza infection", "inhibitor", "innovation", "myelination", "neural circuit", "neurodevelopment", "neurogenesis", "neuroimmunologic disease", "neuroimmunology", "oligodendrocyte differentiation", "oligodendrocyte progenitor", "optogenetics", "postnatal", "prenatal", "reconstruction", "respiratory", "single nucleus RNA-sequencing", "skills", "success", "synaptic pruning", "synaptogenesis", "therapy development", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "16038", "attributes": { "award_id": "1R56AI193005-01A1", "title": "Advancing a novel oral anti-IAV therapeutic to the clinic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32536, "first_name": "DIPANWITA", "last_name": "BASU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-08-11", "end_date": "2027-07-31", "award_amount": 1265732, "principal_investigator": { "id": 21861, "first_name": "JEFFREY S", "last_name": "GLENN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 3380, "ror": "", "name": "STANFORD UNIVERSITY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT: Our overall objective is to develop a new class of direct acting antivirals (DAAs) against influenza A virus (IAV) infections, which can cause devastating pandemics of far greater mortality than COVID-19. Ideally, such therapeutics will be oral (for convenient outpatient use), a small molecule (for ease in manufacturing, storage, and distribution), of orthogonal mechanism of action (MOA) to currently available drugs (to maximize the potential for synergy with, or mitigating the development of resistance to, current therapeutics), and have demonstrated proof-of-concept in vivo efficacy against IAV in an animal model. Our preliminary data with our lead molecule, STF-8562, demonstrates that it meets all these criteria. In particular, our molecule’s MOA is distinct from Tamiflu, Baloxavir, and amantadine, and is fully active against IAV resistant to these three drugs. Our molecule targets the amphipathic helix (AH) motif in the IAV M2 protein, and provides 100% protection against a lethal inoculum of IAV in mice—even when administered 3 days after infection (at a time when Tamiflu and Baloxavir are ineffective). Moreover, we have developed two lead series that appear to target different aspects of the M2 AH, and are highly synergistic with each other. Thus, their optimization as proposed here can enable the best from one series to be nominated as the development candidate and the best of the second series to serve as back up as well as a possible synergistic partner. Finally, our latest leads have promising attributes for a successful IND, including no significant activity against hERG channels and good tolerability at high doses in rats. Although they could be developed as is, we hypothesize that: 1) our leads can be further optimized to enable once daily administration with a still lower dose; 2) our biochemical assay measuring the interaction of compound with its peptide target within IAV can assist with these efforts; 3) our knowledge of our leads’ major metabolites can guide optimization to increase in vivo metabolic stability; and 4) based on our current and to be obtained data, we can develop a successful IND package to enable an exciting new class of anti-IAV DAAs to enter the clinic. We propose to test these hypotheses via the following specific aims: 1) perform a focused medicinal chemistry effort to optimize our current lead molecules’ potency and pharmacokinetics to enable once daily dosing and nominate a lead inhibitor, and back-up molecule, to take into IND-enabling studies; 2) expand the virology data package by performing in vitro and in vivo selection for resistance studies, assessing efficacy against additional IAV strains, and performing combination experiments with other existing anti-IAV agents; 3) nominate an IND candidate by developing a process and analytical methods to manufacture non-GMP and GMP API, preparing an optimal formulation, and performing in vitro ADME-Tox, and non-GLP and GLP toxicity studies in rats and dogs; and 4) assemble an IND package to enable human clinical testing. Successful accomplishment of our aims will yield an exciting new class of oral small molecules--that we term M2AH--inhibitors, which can be used alone or in combination with other antivirals to counter seasonal and potential pandemic IAV strains.", "keywords": [ "Amantadine", "Animal Model", "Anti-viral Agents", "Back", "Biochemical", "Biological Assay", "Biological Availability", "Biology", "COVID-19 mortality", "Canis familiaris", "Chemistry", "Clinic", "Data", "Development", "Dose", "Drug Kinetics", "Ferrets", "Formulation", "Human", "In Vitro", "Infection", "Influenza", "Influenza A virus", "Influenza A virus M2 protein", "Investigational New Drug Application", "Knowledge", "Lead", "M2 protein", "Measures", "Metabolic", "Mus", "Oral", "Oseltamivir", "Outpatients", "Peptides", "Pharmaceutical Chemistry", "Pharmaceutical Preparations", "Prevention", "Process", "Property", "Rattus", "Regulatory Affairs", "Resistance", "Resistance development", "Seasons", "Series", "Testing", "Therapeutic", "Time", "Toxic effect", "Toxicology", "Viral", "Viral Physiology", "Virus Diseases", "analytical method", "anti-influenza", "drug development", "efficacy evaluation", "efficacy validation", "experimental study", "in vivo", "industry partner", "influenza virus strain", "inhibitor", "lead series", "manufacture", "multidisciplinary", "novel", "pandemic disease", "pandemic influenza", "pandemic potential", "research clinical testing", "small molecule", "synergism", "transmission process", "virology" ], "approved": true } }, { "type": "Grant", "id": "15856", "attributes": { "award_id": "1R43AG094486-01", "title": "Characterizing neurocognitive deficits in post-acute sequelae of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44278, "first_name": "DAVID WITT", "last_name": "FRANKOWSKI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-16", "end_date": "2027-05-31", "award_amount": 325672, "principal_investigator": { "id": 44279, "first_name": "Jennifer", "last_name": "Graves", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44280, "first_name": "Amir Hossein", "last_name": "Meghdadi", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3381, "ror": "", "name": "ADVANCED BRAIN MONITORING, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Post-acute sequelae of COVID-19 (PASC), or Long COVID, is an emerging global health crisis with an urgent need for objective assessment tools to quantify neurocognitive deficits. This proposal aims to validate and leverage a novel mobile electroencephalography (EEG) platform to provide accessible, cost-effective cognitive assessments for individuals suffering from neurological manifestations of PASC (nPASC). Our preliminary data suggests that EEG/event-related potential (ERP) biosignatures, including delayed neural responses during auditory and memory tasks, are sensitive to cognitive impairments in nPASC. However, the trajectory and specificity of these deficits remain unclear. This study will validate these preliminary findings in a larger cohort (n=52) and longitudinally monitor changes over one year to map recovery or detect early signs of persistent cognitive decline. The innovative approach integrates resting-state EEG with multiple task-based ERP protocols, enabling comprehensive profiling of neural dysfunction associated with nPASC. Leveraging Advanced Brain Monitoring's FDA-cleared mobile EEG platform and validated analysis pipelines will provide a scalable solution for widespread clinical use and remote assessments. If successful, this study will deliver a quantitative EEG/ERP biomarker profile specific to neuro-PASC, enabling objective evaluation of cognitive deficits. Longitudinal monitoring will elucidate the natural trajectory, identify potential risk factors for persistent impairment, and provide outcome measures for future therapeutic interventions. This innovative diagnostic tool will empower patients and clinicians by providing objective evidence of nPASC severity and treatment efficacy.", "keywords": [ "2019-nCoV", "Acute", "Address", "Age", "Algorithms", "Alzheimer's Disease", "Anxiety", "Assessment tool", "Attention", "Auditory", "Brain", "COVID-19", "COVID-19 patient", "COVID-19 severity", "COVID-19 treatment", "Central Nervous System", "Clinical", "Cognition", "Cognitive", "Cognitive deficits", "Control Groups", "Data", "Diagnosis", "Early Diagnosis", "Electroencephalography", "Empirical Research", "Evaluation", "Event-Related Potentials", "Exhibits", "Fatigue", "Future", "Health Professional", "Heterogeneity", "High Prevalence", "Impaired cognition", "Impairment", "Individual", "Infection", "Long COVID", "Maps", "Memory", "Mental Depression", "Methods", "Modality", "Monitor", "Nature", "Neurocognitive Deficit", "Neurologic", "Neurologic Symptoms", "Neuronal Dysfunction", "Outcome", "Outcome Measure", "Participant", "Pathway interactions", "Patient Self-Report", "Patients", "Phase", "Pilot Projects", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Process", "Protocols documentation", "Public Health", "Quality of life", "Random Allocation", "Recovery", "Reporting", "Reproducibility", "Research", "Rest", "Risk", "Risk Factors", "Sample Size", "Self Assessment", "Severities", "Specificity", "Statistical Models", "Symptoms", "Techniques", "Technology", "Therapeutic Intervention", "Time", "Treatment Efficacy", "Validation", "Visit", "analysis pipeline", "auditory processing", "biomarker identification", "biosignature", "case control", "cognitive task", "cognitive testing", "cohort", "cost effective", "cost efficient", "data acquisition", "design", "diagnostic tool", "effective intervention", "empowerment", "epidemiology study", "executive function", "experience", "follow-up", "global health", "innovation", "machine learning model", "mild cognitive impairment", "neural", "neural correlate", "neurologic sequelae of COVID-19", "neuropathology", "neurophysiology", "neuropsychiatry", "novel", "post-COVID-19", "potential biomarker", "primary endpoint", "remote assessment", "response", "specific biomarkers", "symptomatology", "therapy development", "trend", "visual memory" ], "approved": true } }, { "type": "Grant", "id": "15858", "attributes": { "award_id": "1SB1AI191871-01A1", "title": "Development of highly potent human monoclonal for RSV immunoprophylaxis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21312, "first_name": "SONNIE", "last_name": "KIM", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-24", "end_date": "2028-08-31", "award_amount": 993353, "principal_investigator": { "id": 44282, "first_name": "Ellen", "last_name": "Monson", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44283, "first_name": "Larry", "last_name": "Zeitlin", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3382, "ror": "", "name": "MAPP BIOPHARMACEUTICAL, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Globally, respiratory syncytial virus (RSV) causes over 3 million hospitalizations of neonates/infants. While there are licensed vaccines in the U.S. for use in elderly populations, they are neither approved nor appropriate for use in neonates/infants who have immature immune systems. Palivizumab, a prophylactic monoclonal antibody (mAb) marketed by AstraZeneca and Sobi as Synagis™, has been available since 1998, but due to high cost and modest efficacy, its use has been restricted to high-risk infants. The recently approved single dose, long-acting mAb, nirsevimab (previously known as MEDI8897 and marketed as Beyfortus™ by Sanofi), has improved efficacy compared to palivizumab and was approved for use in all children up to 24 months of age. However, severe shortages and cost barriers have limited its availability in countries where it is currently approved (EU, US, Japan, Australia, Canada and China). In October 2023 the CDC issued Health Alert Network CDCHAN-00499 that recommended limiting the use of nirsevimab to higher risk children in the 2023- 2024 season due to the shortages, resulting in many eligible infants not receiving prophylaxis. In addition, nirsevimab is not currently available in any low- or middle-income countries (LMICs) and is unavailable in 8/10 of the most populous countries in the world. Mapp Biopharmaceutical, Inc. is developing a fully human mAb product, MBP002, that like nirsevimab, can be administered in a single dose per RSV season. Mapp’s objective is to dramatically lower the price and increase the global availability of RSV immunoprophylaxis. Further, unlike nirsevimab and Merck’s Phase 3 candidate, MK-1654, Mapp’s product is a two mAb cocktail, reducing the risk not only of clinical development of resistance, but also of a naturally occurring strain evading a single mAb. Indeed, this method of product failure occurred during a recent Phase 3 trial with Regeneron’s RSV mAb candidate and is the reason several mAb candidates lost their emergency use authorization for use against COVID-19. While nirsevimab resistant mutations were rare in a survey of 5675 RSV strains between 2015 and 2021, several mutations in the nirsevimab binding site have increased since 2020, including the resistant RSV-B variant K68N present in the U.S. and Australia. The impact of widespread use of nirsevimab on the frequency of resistant variants is under close post-marketing surveillance due to the potential for selection of escape mutants. Mapp has screened 70+ RSV clinical strains and found neutralization resistant strains to palivizumab, nirsevimab (MEDI8897) and Regeneron’s candidate, but no resistant strains to one of the MBP002 mAbs. In addition, the MBP002 mAbs are dramatically more potent in vitro and in vivo than palivizumab and have comparable neutralization and in vivo activity to nirsevimab. The requested SBIR support, together with significant in-kind contributions by Mapp, will allow for the advancement of MBP002 to IND submission (Investigational New Drug Application) and initiation of a Phase 1 clinical trial.", "keywords": [ "2 year old", "Adult", "Age Months", "Age Years", "Antibodies", "Asthma", "Australia", "Binding Sites", "Biological Assay", "Biological Products", "COVID-19", "Canada", "Child", "Childhood", "China", "Chronic lung disease", "Clinical", "Congestive Heart Failure", "Country", "Development", "Development Plans", "Dose", "Drug Kinetics", "Elderly", "Eligibility Determination", "Escape Mutant", "Experimental Designs", "FDA Emergency Use Authorization", "Failure", "Frequencies", "Health", "Hospitalization", "Hospitals", "Immune system", "In Vitro", "Income", "Infant", "Influenza A virus", "Investigational New Drug Application", "Japan", "Licensing", "Ligand Binding", "Lower respiratory tract structure", "Marketing", "Methods", "Monoclonal Antibodies", "Mutation", "Nursing Homes", "Palivizumab", "Pharmaceutical Preparations", "Phase", "Phase I Clinical Trials", "Population", "Price", "Prophylactic treatment", "Recommendation", "Rehabilitation therapy", "Resistance", "Resistance development", "Respiratory Tract Diseases", "Respiratory syncytial virus", "Risk Reduction", "Seasons", "Small Business Innovation Research Grant", "Surveys", "Testing", "Toxicology", "Vaccines", "Validation", "Variant", "Virus Diseases", "Wheezing", "burden of illness", "clinical development", "comparative efficacy", "cost", "high risk", "high risk infant", "human monoclonal antibodies", "human old age (65+)", "immunoprophylaxis", "improved", "in vivo", "low and middle-income countries", "manufacture", "method development", "neonate", "phase III trial", "post-market", "prevent", "prophylactic", "resistance mutation", "resistant strain" ], "approved": true } }, { "type": "Grant", "id": "15860", "attributes": { "award_id": "1R35GM156197-01", "title": "Pathological Autoantibodies Contribute to Immune Suppression in Sepsis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 44285, "first_name": "XIAOLI", "last_name": "ZHAO", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-01", "end_date": "2030-07-31", "award_amount": 410000, "principal_investigator": { "id": 44286, "first_name": "Gerard J", "last_name": "Nau", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3383, "ror": "", "name": "RHODE ISLAND HOSPITAL", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "Sepsis is a severe illness associated with high morbidity and mortality in the US and globally. Complications of multi-organ dysfunction, acute respiratory distress syndrome, and infections have a significant impact on late survival. With limited therapeutic interventions, it is essential to understand the fundamental biology of sepsis. Immune dysfunction and immunosuppression are characteristic of sepsis, especially with late complications where lymphopenia predicts a poor prognosis. Gaps remain, however, in the understanding of the mechanisms underlying prolonged immune suppression. Recently, there has been a greater appreciation of autoimmune antibodies that lead to pathological immune consequences in the setting of critical illness. For example, sepsis due to COVID-19 leads to anti-cytokine autoantibodies (ACAAs) that correlate with greater disease severity. In our preliminary data we have also defined ACAAs post-COVID along with ACAAs in ICU patients with sepsis. We have also made the novel discovery of anti-Fas autoantibodies (FasAAs) induced during sepsis, representing a novel mechanism for lymphopenia associated with critical illness. Our overarching hypothesis is that severe conditions like sepsis induce pathological autoimmunity that alters immune function and increases infections. Our hypothesis predicts that sepsis patients with higher levels of autoantibodies will have more immune dysregulation and secondary infectious complications. The objective of this proposal is to determine the prevalence of ACAAs, define mechanism(s) by which they contribute to immunosuppression, and identify sites where their activity could be disrupted for therapeutic purposes. We propose using complementary immune and computational approaches to identify autoantibodies from the blood of sepsis patients and how they correlate with clinical status. We will investigate the biological function of these antibodies on human cytokines and human cells in vitro, along with developing strategies to interfere with deleterious autoantibodies. To address these issues, we have obtained over 350 serum specimens for this study to discriminate between the effects of preexisting autoantibodies and those with a net increase during sepsis. In addition, we have access to deep RNA-seq data from over 100 sepsis patients for computational studies. The long-term objective is to apply this information to assess prognosis of sepsis patients and create precision therapeutics to sustain and restore immune function.", "keywords": [ "Acute Respiratory Distress Syndrome", "Address", "Antibodies", "Autoantibodies", "Autoimmunity", "Biological Process", "Biology", "Blood", "COVID-19", "Cells", "Characteristics", "Clinical", "Critical Illness", "Data", "Functional disorder", "Human", "Immune", "Immune System Diseases", "Immune system", "Immunosuppression", "In Vitro", "Infection", "Lymphopenia", "Modality", "Morbidity - disease rate", "Organ", "Pathologic", "Patients", "Precision therapeutics", "Prevalence", "Prognosis", "Proteins", "Research", "Sepsis", "Serum", "Severity of illness", "Site", "Specimen", "Therapeutic", "Therapeutic Intervention", "computer studies", "cytokine", "immune function", "infection risk", "mortality", "novel", "novel therapeutics", "post sepsis", "post-COVID-19", "preservation", "septic patients", "transcriptome sequencing" ], "approved": true } }, { "type": "Grant", "id": "15862", "attributes": { "award_id": "1R44AG097298-01", "title": "Scaling a network of small community-based care homes as a high-value alternative to institutional care", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 44288, "first_name": "ERIN", "last_name": "HARRELL", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-16", "end_date": "2027-05-31", "award_amount": 1089329, "principal_investigator": { "id": 44289, "first_name": "Vipan", "last_name": "Nikore", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3384, "ror": "", "name": "HOMECARE HUB US INC", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "The United States faces a severe long-term services and supports (LTSS) crisis as the senior population grows rapidly, with the number of seniors expected to nearly double by 2060. Approximately 70% of these individuals will require some form of LTSS, putting unprecedented pressure on a system that is already costly and strained. Traditional nursing homes, while necessary, frequently exceed $100,000 annually per patient and often lead to issues such as social isolation, high readmission rates, and lower resident satisfaction. The COVID-19 pandemic underscored the fragility of these centralized care models, which saw higher infection rates, limited adaptability, and increasing burdens on families and health systems. There is an urgent need for cost-effective, high-quality, and scalable non-institutional LTSS alternatives that are adaptable to the needs of seniors. Homecare Hub (HCH) offers an innovative solution through its network of small, community-based 2-12 person residential care homes. By creating a technology and services platform that allows caring nurses and caregivers to create new supply of high-quality small care homes, and then connecting seniors to these new and existing vetted small homes that deliver personalized, cost-effective care, HCH aims to provide a decentralized, supportive alternative to institutional LTSS. This model leverages a robust technology platform to monitor real-time bed availability in the network of homes, facilitate efficient patient transitions, and uphold high standards of quality. This makes HCH a natural fit within the healthcare ecosystem. HCH’s solution has already demonstrated notable success, achieving reduced hospital readmissions, shorter lengths of stay, and high family satisfaction across multiple pilot studies. The project’s specific aims are: 1) to demonstrate improved health outcomes for seniors by tracking measures in physical health (chronic disease management), mental health, and overall well-being, as well as reductions in ER visits and re-admissions; 2) to quantify the cost-effectiveness of HCH’s model through comparative analyses with traditional LTSS, showing potential for significant healthcare savings; and 3) to highlight how this model supports enhanced hospital throughput and transitions by enabling faster, more efficient and higher quality discharges. By fostering a model that addresses both the financial and human challenges of LTSS, HCH is poised to make a transformative impact on the healthcare system, providing a sustainable, person-centered approach to senior care that enhances quality, reduces costs, and aligns with the future of value-based healthcare.", "keywords": [ "Acute", "Address", "Adoption", "Assisted Living Facilities", "Beds", "COVID-19 pandemic", "Care given by nurses", "Caregivers", "Caring", "Chronic Disease", "Client satisfaction", "Communities", "Computer software", "Continuity of Patient Care", "Country", "Data", "Death Rate", "Decentralization", "Disease Management", "Ecosystem", "Emergency department visit", "Ensure", "Face", "Family", "Financial Hardship", "Fostering", "Future", "Gerontology", "Goals", "Growth", "Health", "Health Care", "Health Care Costs", "Health Care Systems", "Health Surveys", "Health system", "Home", "Hospitalization", "Hospitals", "Human", "Individual", "Infection", "Infrastructure", "Institution", "Interview", "Length of Stay", "Life Style", "Link", "Long-Term Care", "Mainstreaming", "Marketing", "Measurable", "Measures", "Medical Care Team", "Mental Health", "Modeling", "North America", "Nursing Homes", "Outcome", "Paper", "Pathway interactions", "Patient-Focused Outcomes", "Patients", "Personal Satisfaction", "Persons", "Phase", "Pilot Projects", "Population", "Positioning Attribute", "Process", "Quality of Care", "Residential Treatment", "Resources", "Risk", "Savings", "Services", "Skilled Nursing Facilities", "Social isolation", "Support System", "Surveys", "System", "Technology", "Time", "Traction", "United States", "Visit", "Wisconsin", "aging population", "care costs", "care outcomes", "care systems", "clinical care", "community based care", "comparative", "cost", "cost effective", "cost effectiveness", "cost efficient", "experience", "family burden", "flexibility", "health record", "high standard", "hospital readmission", "improved", "infection rate", "innovation", "patient home care", "person centered", "personalized care", "physical conditioning", "preference", "pressure", "readmission rates", "real time monitoring", "resilience", "satisfaction", "social", "success", "technology platform", "value-based care" ], "approved": true } }, { "type": "Grant", "id": "15863", "attributes": { "award_id": "1R01AI187511-01A1", "title": "Integrating genomic architecture and tuberculosis (TB) immunity in Africa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32562, "first_name": "KAREN A", "last_name": "LACOURCIERE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-17", "end_date": "2030-08-31", "award_amount": 802499, "principal_investigator": { "id": 24650, "first_name": "Paul John", "last_name": "Norman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 3385, "ror": "", "name": "UNIVERSITY OF COLORADO DENVER", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Modified Project Summary/Abstract Section The human obligate bacterium Mycobacterium tuberculosis (M.tb) infects approximately a quarter of the world's population, leading to chronic disease with an annual death toll exceeding 1.6 million. The disruption of services during the COVID-19 pandemic resulted in a 4.5% increase in cases, exceeding 6 million new cases in 2021, with Africa bearing a critical burden. The incidence in USA is increasing by 16% per year. Not all infected individuals progress to active disease, and we have shown in genome-wide association studies (GWAS) that human host genetic factors contribute to disease outcome. To identify new ways to improve disease outcome, human studies to characterize the genetic factors involved in TB and its interaction with the immune system are urgently needed. Here, we focus on the genetic susceptibility to active TB, focusing on HLA and its interactions with the KIR genes of natural killer (NK) cells, critical in shaping the immune response against TB. In this study, we propose to uniquely leverage the diversity of South African populations (sub-Saharan African, European, and South-East Asian ancestries) to perform multi-ethnic associations with broad applicability. Specifically, we aim to: 1) Generate population-level data (HLA, KIR, and SNP array) on 5,000 case/control samples, characterizing genetic diversity across multi-ancestry individuals from South Africa; 2) Perform binding and cytotoxic assays to functionally test/develop interaction scores for newly discovered alleles, and determine their specific NK impact on NK cell function 3) Develop appropriate, well-powered statistical models for association of HLA/KIR variation and HLA/KIR interaction with disease susceptibility. The Northern Cape Province, South Africa provides an ideal location to perform this study; the extremely high community TB incidence results in lower misclassification bias introduced by unknown or low infectious disease exposure. Outcomes include: a) studying a large TB case-control dataset of DNA, clinically-active cases and epidemiological variables of 5,000 participants; b) clarifying the role of NK cells in TB pathogenesis; c) appropriately calibrated statistical models of HLA/KIR association in admixed populations. We have an outstanding track record of collaboration, including ≥ 40 co-authored publications, as well as expertise in clinical epidemiology, statistical and population genetics, and immunogenetics, uniquely positioning us to address this critical research question using innovative methods -- including direct HLA and KIR allele sequencing and functional validation of their interactions. Through direct genetic assays, complex interaction analyses, and advanced statistical approaches, this study aims to shed light on the genetic risk factors and the immunogenetic landscape critical for understanding and combatting TB.", "keywords": [ "Address", "Adult", "Africa", "African", "Alleles", "Antibody Formation", "Architecture", "Asian ancestry", "Bacteria", "Binding", "Biological Assay", "COVID-19", "COVID-19 pandemic", "Calibration", "Cause of Death", "Cell Communication", "Cell Line", "Cell Physiology", "Cells", "Cessation of life", "Characteristics", "Chronic", "Chronic Disease", "Clinical", "Collaborations", "Collection", "Communicable Diseases", "Communities", "Complex", "Country", "DNA", "Data", "Data Set", "Development", "Disease", "Disease Outcome", "Disease susceptibility", "Environment", "Epidemiology", "European", "Freedom", "Functional disorder", "Gene Fusion", "Genes", "Genetic", "Genetic Polymorphism", "Genetic Predisposition to Disease", "Genetic Variation", "Genomics", "HLA Antigens", "Heritability", "Heterogeneity", "Histocompatibility Antigens Class I", "Histocompatibility Antigens Class II", "Human", "Immune response", "Immune system", "Immunity", "Immunogenetics", "Immunoglobulins", "Incidence", "Individual", "KIR3DS1", "Killer Cells", "Laboratories", "Ligands", "Location", "Maps", "Methods", "Mycobacterium tuberculosis", "Natural Killer Cells", "Outcome", "Participant", "Pathogenesis", "Peptides", "Population", "Population Genetics", "Positioning Attribute", "Predisposition", "Prevalence", "Province", "Publications", "Receptor Cell", "Receptor Gene", "Research", "Resistance", "Resolution", "Role", "SNP array", "Sample Size", "Sampling", "Services", "Shapes", "Signal Transduction", "South Africa", "South African", "Southern Africa", "Statistical Models", "Testing", "Tuberculosis", "Tuberculosis diagnosis", "Validation", "Variant", "case control", "clinical epidemiology", "cohort", "combinatorial", "cytotoxic", "dosage", "genetic association", "genetic risk factor", "genome wide association study", "genome-wide", "genomic locus", "human model", "improved", "innovation", "insight", "large datasets", "microbial", "multi-ethnic", "nanopore sequencing", "novel", "population stratification", "public health relevance", "receptor", "receptor expression", "reference genome", "response", "segregation", "southeast Asian", "structural mutation", "tuberculosis immunity" ], "approved": true } } ], "meta": { "pagination": { "page": 1424, "pages": 1442, "count": 14420 } } }